DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
John P. Pigott, MD, FACS, currently serves as Chief Innovations Officer/Strategic Business Development for ProMedica and ProMedica Innovations, where he works with thought leaders...
David Finkel is the Founder and CEO of Maui Mastermind®, one of the world’s premier business coaching companies with thousands of clients worldwide. He...
Recalibrate Solutions (RS) is creating a stethoscope for stress health monitoring of kids. It’s a 5-minute, disposable cortisol test that helps identify kids suffering...
